11.02.16
Allergan
3Q Revenues: $3.6 billion (+4%)
3Q Earnings: $15.2 billion (earnings were $5.2 billion 3Q15)*
YTD Revenues: $10.7 billion (+18%)
YTD Earnings: $15.0 billion (earnings were $4.5 billion YTD15)*
Comments: Growth in the quarter was driven key brands and new product launches, offset by the loss of ASACOL HD exclusivity, lower revenues for NAMENDA XRand IR, a decline in non-promoted Established Brands revenues and unfavorable foreign exchange. ASACOL sales were down to $72.2 million in the quarter. NAMENDA sales were $146.9 million, down 32%. RESTASIS revenues in the quarter were $356.4 million, up 14%. BOTOX Cosmetic revenues were $174.5 million, up 10% and BOTOX Therapeutic revenues were $305.5 million, up 17% driven by strong demand across overactive bladder, chronic migraine and adult spasticity indications.
*Earnings reflect income from discontinued operations, including the divestiture of the company's Global Generics business to Teva on August 2, 2016.
3Q Revenues: $3.6 billion (+4%)
3Q Earnings: $15.2 billion (earnings were $5.2 billion 3Q15)*
YTD Revenues: $10.7 billion (+18%)
YTD Earnings: $15.0 billion (earnings were $4.5 billion YTD15)*
Comments: Growth in the quarter was driven key brands and new product launches, offset by the loss of ASACOL HD exclusivity, lower revenues for NAMENDA XRand IR, a decline in non-promoted Established Brands revenues and unfavorable foreign exchange. ASACOL sales were down to $72.2 million in the quarter. NAMENDA sales were $146.9 million, down 32%. RESTASIS revenues in the quarter were $356.4 million, up 14%. BOTOX Cosmetic revenues were $174.5 million, up 10% and BOTOX Therapeutic revenues were $305.5 million, up 17% driven by strong demand across overactive bladder, chronic migraine and adult spasticity indications.
*Earnings reflect income from discontinued operations, including the divestiture of the company's Global Generics business to Teva on August 2, 2016.